Meng X, Zhu X, Li B, Liu J, Zhao J, Wang H
Exp Ther Med. 2023; 25(6):273.
PMID: 37206569
PMC: 10189747.
DOI: 10.3892/etm.2023.11971.
Wang S, Zha G, Rakesh K, Darshini N, Shubhavathi T, Vivek H
Medchemcomm. 2018; 8(6):1173-1189.
PMID: 30108827
PMC: 6072339.
DOI: 10.1039/c7md00111h.
Ferreira P, de Oliveira C, Braga de Oliveira A, Lopes M, Alzamora F, Ribeiro Vieira M
Planta. 2004; 219(2):319-24.
PMID: 15014995
DOI: 10.1007/s00425-004-1222-9.
Hussain F, Ajjan R, Moustafa M, Weir N, Riley S
Br J Clin Pharmacol. 1998; 46(2):173-5.
PMID: 9723828
PMC: 1873662.
DOI: 10.1046/j.1365-2125.1998.00762.x.
GAN K, Geus W, Lamers C, Heijerman H
Dig Dis Sci. 1997; 42(11):2304-9.
PMID: 9398810
DOI: 10.1023/a:1018827003641.
Gastric ulcers differ from duodenal ulcers. Evaluation of basal acid output.
Collen M, Sheridan M
Dig Dis Sci. 1993; 38(12):2281-6.
PMID: 8261834
DOI: 10.1007/BF01299909.
Safety of acid-suppressing drugs.
Smallwood R, Berlin R, Castagnoli N, Festen H, Hawkey C, Lam S
Dig Dis Sci. 1995; 40(2 Suppl):63S-80S.
PMID: 7859585
DOI: 10.1007/BF02214872.
Omeprazole in the management of sclerotherapy-induced esophageal ulcers resistant to H2 blocker treatment.
Jaspersen D, Korner T, Schorr W, HAMMAR C
J Gastroenterol. 1995; 30(1):128-30.
PMID: 7719407
DOI: 10.1007/BF01211388.
The effect of omeprazole on gastric emptying in patients with duodenal ulcer disease.
Horowitz M, Hetzel D, Buckle P, Chatterton B, Shearman D
Br J Clin Pharmacol. 1984; 18(5):791-4.
PMID: 6508988
PMC: 1463542.
DOI: 10.1111/j.1365-2125.1984.tb02544.x.
Omeprazole: effects on oxidative drug metabolism.
Henry D, Somerville K, Kitchingman G, Langman M
Br J Clin Pharmacol. 1984; 18(2):195-200.
PMID: 6487457
PMC: 1463522.
DOI: 10.1111/j.1365-2125.1984.tb02452.x.
Optimal dose of oral omeprazole for maximal 24 hour decrease of intragastric acidity.
Sharma B, Walt R, Pounder R, Gomes M, Wood E, LOGAN L
Gut. 1984; 25(9):957-64.
PMID: 6469081
PMC: 1432495.
DOI: 10.1136/gut.25.9.957.
Oral pharmacokinetics of omeprazole.
Howden C, MEREDITH P, Forrest J, Reid J
Eur J Clin Pharmacol. 1984; 26(5):641-3.
PMID: 6468483
DOI: 10.1007/BF00543502.
Omeprazole inhibits nocturnal and pentagastrin-stimulated gastric secretion in man.
Wilson J, Boyd E, Wormsley K
Dig Dis Sci. 1984; 29(9):797-801.
PMID: 6432499
DOI: 10.1007/BF01318421.
Effect of daily oral omeprazole on 24 hour intragastric acidity.
Prichard P, Yeomans N, Mihaly G, Jones D, Smallwood R, Louis W
Br Med J (Clin Res Ed). 1983; 287(6402):1378-9.
PMID: 6416424
PMC: 1549507.
DOI: 10.1136/bmj.287.6402.1378-c.
Duodenal ulcers that will not heal.
Pounder R
Gut. 1984; 25(7):697-702.
PMID: 6329922
PMC: 1432595.
DOI: 10.1136/gut.25.7.697.
Effects of loxtidine, a new histamine H2-receptor antagonist, on 24-hour gastric secretion in man.
Boyd E, Wormsley K
Eur J Clin Pharmacol. 1984; 26(4):443-7.
PMID: 6145595
DOI: 10.1007/BF00542138.
Medical management of peptic ulcer.
Misiewicz J
Postgrad Med J. 1984; 60(709):751-9.
PMID: 6095240
PMC: 2418060.
DOI: 10.1136/pgmj.60.709.751.
Omeprazole, a gastric 'proton pump inhibitor': lack of effect on renal handling of electrolytes and urinary acidification.
Howden C, Reid J
Eur J Clin Pharmacol. 1984; 26(5):639-40.
PMID: 6088253
DOI: 10.1007/BF00543501.
Antisecretory effect and oral pharmacokinetics of omeprazole in patients with chronic renal failure.
Howden C, Payton C, MEREDITH P, Hughes D, MACDOUGALL A, Reid J
Eur J Clin Pharmacol. 1985; 28(6):637-40.
PMID: 4065187
DOI: 10.1007/BF00607907.
Effects of single daily doses of a pyridil-2-tetrahydrothiophene derivative (40749 RP) on 24 hour H+ activity, nocturnal acid output, gastrin and pepsinogen I profiles in duodenal ulcer patients.
Male P, Griessen M, Cunningham M, Frydman A, de Peyer R, Loizeau E
Gut. 1986; 27(4):423-7.
PMID: 3957110
PMC: 1433377.
DOI: 10.1136/gut.27.4.423.